-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Noroviruses -X- _ B-Patient
and -X- _ I-Patient
rotaviruses -X- _ I-Patient
are -X- _ O
important -X- _ O
viral -X- _ O
etiologies -X- _ O
of -X- _ O
severe -X- _ O
gastroenteritis. -X- _ O
Noroviruses -X- _ O
are -X- _ O
the -X- _ O
primary -X- _ O
cause -X- _ O
of -X- _ O
nonbacterial -X- _ O
diarrheal -X- _ O
outbreaks -X- _ O
in -X- _ O
humans -X- _ O
, -X- _ O
whilst -X- _ O
rotaviruses -X- _ O
are -X- _ O
a -X- _ O
major -X- _ O
cause -X- _ O
of -X- _ O
childhood -X- _ O
diarrhea. -X- _ O
Although -X- _ O
both -X- _ O
enteric -X- _ O
pathogens -X- _ O
substantially -X- _ O
impact -X- _ O
human -X- _ O
health -X- _ O
and -X- _ O
economies -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
approved -X- _ O
drugs -X- _ O
against -X- _ O
noroviruses -X- _ B-Patient
and -X- _ I-Patient
rotaviruses -X- _ I-Patient
so -X- _ O
far. -X- _ O
On -X- _ O
the -X- _ O
other -X- _ O
hand -X- _ O
, -X- _ O
whilst -X- _ O
the -X- _ O
currently -X- _ O
licensed -X- _ O
rotavirus -X- _ O
vaccines -X- _ O
have -X- _ O
been -X- _ O
successfully -X- _ O
implemented -X- _ O
in -X- _ O
over -X- _ O
100 -X- _ O
countries -X- _ O
, -X- _ O
the -X- _ O
most -X- _ O
advanced -X- _ O
norovirus -X- _ O
vaccine -X- _ O
has -X- _ O
recently -X- _ O
completed -X- _ O
phase-I -X- _ O
and -X- _ O
II -X- _ O
trials. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
performed -X- _ O
a -X- _ O
structured -X- _ O
search -X- _ O
of -X- _ O
bibliographic -X- _ O
databases -X- _ O
for -X- _ O
peer-reviewed -X- _ O
research -X- _ O
litera-ture -X- _ O
on -X- _ O
advances -X- _ O
in -X- _ O
the -X- _ O
fields -X- _ O
of -X- _ O
norovirus -X- _ B-Patient
and -X- _ I-Patient
rotavirus -X- _ I-Patient
therapeutics -X- _ B-Intervention
and -X- _ I-Intervention
immunoprophylaxis. -X- _ I-Intervention
RESULTS -X- _ O
: -X- _ O
Technological -X- _ O
advances -X- _ O
coupled -X- _ O
with -X- _ O
a -X- _ O
proper -X- _ O
understanding -X- _ O
of -X- _ O
viral -X- _ O
morphology -X- _ O
and -X- _ O
replication -X- _ O
over -X- _ O
the -X- _ O
past -X- _ O
decade -X- _ O
has -X- _ O
facilitated -X- _ O
pioneering -X- _ O
research -X- _ O
on -X- _ O
therapeutics -X- _ B-Intervention
and -X- _ I-Intervention
immunoprophylaxis -X- _ I-Intervention
against -X- _ O
noroviruses -X- _ B-Patient
and -X- _ I-Patient
rotaviruses -X- _ I-Patient
, -X- _ O
with -X- _ O
promising -X- _ O
outcomes -X- _ O
in -X- _ O
human -X- _ O
clinical -X- _ O
trials -X- _ O
of -X- _ O
some -X- _ O
of -X- _ O
the -X- _ O
drugs -X- _ O
and -X- _ O
vaccines. -X- _ O
This -X- _ O
review -X- _ O
focuses -X- _ O
on -X- _ O
the -X- _ O
various -X- _ O
developments -X- _ O
in -X- _ O
the -X- _ O
fields -X- _ O
of -X- _ O
norovirus -X- _ B-Patient
and -X- _ I-Patient
rotavirus -X- _ I-Patient
thera-peutics -X- _ B-Intervention
and -X- _ I-Intervention
immunoprophylaxis -X- _ I-Intervention
, -X- _ O
such -X- _ O
as -X- _ O
potential -X- _ B-Outcome
antiviral -X- _ I-Outcome
drug -X- _ I-Outcome
molecules -X- _ I-Outcome
, -X- _ I-Outcome
passive -X- _ I-Outcome
immunotherapies -X- _ I-Outcome
( -X- _ I-Outcome
oral -X- _ I-Outcome
human -X- _ I-Outcome
immunoglobulins -X- _ I-Outcome
, -X- _ I-Outcome
egg -X- _ I-Outcome
yolk -X- _ I-Outcome
and -X- _ I-Outcome
bovine -X- _ I-Outcome
colostral -X- _ I-Outcome
antibodies -X- _ I-Outcome
, -X- _ I-Outcome
llama-derived -X- _ I-Outcome
nanobodies -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
anti-bodies -X- _ I-Outcome
expressed -X- _ I-Outcome
in -X- _ I-Outcome
probiotics -X- _ I-Outcome
, -X- _ I-Outcome
plants -X- _ I-Outcome
, -X- _ I-Outcome
rice -X- _ I-Outcome
grains -X- _ I-Outcome
and -X- _ I-Outcome
insect -X- _ I-Outcome
larvae -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
immune -X- _ I-Outcome
system -X- _ I-Outcome
modulators -X- _ I-Outcome
, -X- _ I-Outcome
probiot-ics -X- _ I-Outcome
, -X- _ I-Outcome
phytochemicals -X- _ I-Outcome
and -X- _ I-Outcome
other -X- _ I-Outcome
biological -X- _ I-Outcome
substances -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
bovine -X- _ I-Outcome
milk -X- _ I-Outcome
proteins -X- _ I-Outcome
, -X- _ I-Outcome
therapeutic -X- _ I-Outcome
nanoparti-cles -X- _ I-Outcome
, -X- _ I-Outcome
hydrogels -X- _ I-Outcome
and -X- _ I-Outcome
viscogens -X- _ I-Outcome
, -X- _ I-Outcome
conventional -X- _ I-Outcome
viral -X- _ I-Outcome
vaccines -X- _ I-Outcome
( -X- _ I-Outcome
live -X- _ I-Outcome
and -X- _ I-Outcome
inactivated -X- _ I-Outcome
whole -X- _ I-Outcome
virus -X- _ I-Outcome
vaccines -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
genetically -X- _ I-Outcome
engineered -X- _ I-Outcome
viral -X- _ I-Outcome
vaccines -X- _ I-Outcome
( -X- _ I-Outcome
reassortant -X- _ I-Outcome
viral -X- _ I-Outcome
particles -X- _ I-Outcome
, -X- _ I-Outcome
virus-like -X- _ I-Outcome
particles -X- _ I-Outcome
( -X- _ I-Outcome
VLPs -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
other -X- _ I-Outcome
sub-unit -X- _ I-Outcome
recombinant -X- _ I-Outcome
vaccines -X- _ I-Outcome
including -X- _ I-Outcome
multi-valent -X- _ I-Outcome
viral -X- _ I-Outcome
vaccines -X- _ I-Outcome
, -X- _ I-Outcome
edible -X- _ I-Outcome
plant -X- _ I-Outcome
vaccines -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
encapsulated -X- _ I-Outcome
viral -X- _ I-Outcome
particles -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
This -X- _ O
review -X- _ O
provides -X- _ O
important -X- _ O
insights -X- _ O
into -X- _ O
the -X- _ O
various -X- _ O
approaches -X- _ O
to -X- _ O
therapeutics -X- _ O
and -X- _ O
im-munoprophylaxis -X- _ O
against -X- _ O
noroviruses -X- _ B-Patient
and -X- _ I-Patient
rotaviruses -X- _ I-Patient
. -X- _ O

